Anti-hepatoma mechanisms of ginsenoside

doi:10.3760/cma.j.issn.1673-422X.2015.10.019

Abstract

Abstract: Ginsenosides (GS) as the main ingredient of ginseng, include dozens of monomer, such as Rg3, Rh2, Rd, Rh1, Rg2, etc. GS and various monomers have different antihepatoma mechanisms. The main mechanism includes the following aspects， inducing the apoptosis of liver cancer cells, inhibiting the proliferation, invasion and metastasis, reversing the multidrug resistance of liver cancer cells, increasing therapeutic effects by combining with other treatments, improving the immune function of organism and inhibiting hepatic glucose production. Different GS monomers play different roles of antihepatoma through their respective channels.

Key words: Ginsenosides, Liver neoplasms, Pharmacology

Zhang Na, Feng Yinglu. Anti-hepatoma mechanisms of ginsenoside[J]. Journal of International Oncology, 2015, 42(10): 786-788.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］ Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2003, 362(9399): 1907-1917. ［3］ Guo XX, Guo Q, Li Y, et al. Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase9/caspase8 activation［J］. Int J Mol Sci, 2012, 13(12): 15523-15535. ［4］ Park HM, Kim SJ, Kim JS, et al. Reactive oxygen species mediated ginsenoside Rg3 and Rh2induced apoptosis in hepatoma cells through mitochondrial signaling pathways［J］. Food Chem Toxicol, 2012, 50(8): 2736-2741. ［5］ Zhu GY, Li YW, Tse AK, et al. 20(S)Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells［J］. Eur J Pharmacol, 2011, 668(1-2): 88-98. ［6］ Zhang C, Liu L, Yu Y, et al. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells［J］. Mol Med Rep, 2012, 5(5): 1295-1298. ［7］ Jiang JW, Chen XM, Chen XH, et al. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway［J］. World J Gastroenterol, 2011, 17(31): 3605-3613. ［8］ Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogenactivated protein kinase signaling pathway in human hepatocellular carcinoma cells［J］. Eur J Pharmacol, 2012, 679(1-3): 24-33. ［9］ Yoon JH, Choi YJ, Cha SW, et al. Antimetastatic effects of ginsenoside Rd via inactivation of MAPK signaling and induction of focal adhesion formation［J］. Phytomedicine, 2012, 19(3-4): 284-292. ［10］ Ming Y, Chen Z, Chen L, et al. Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factorκB p65 and reduction of matrix metalloproteinase2/9［J］. Planta Med, 2011, 77(5): 428-433. ［11］ Shi Q, Li J, Feng Z, et al. Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors［J］. Mol Med Rep, 2014, 10(4): 1779-1785. ［12］ Ho YL, Li KC, Chao W, et al. Korean red ginseng suppresses metastasis of human hepatoma SKHep1 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen activator［J］. Evid Based Complement Alternat Med, 2012, 2012: 965846. ［13］ Lee YS, Lee DG, Lee JY, et al. A formulated red ginseng extract upregulates CHOP and increases TRAILmediated cytotoxicity in human hepatocellular carcinoma cells［J］. Int J Oncol, 2013, 43(2): 591-599. ［14］ Lee JY, Jung KH, Morgan MJ, et al. Sensitization of TRAILinduced cell death by 20(S)ginsenoside Rg3 via CHOPmediated DR5 upregulation in human hepatocellular carcinoma cells［J］. Mol Cancer Ther, 2013, 12(3): 274-285. ［15］ Kim DG, Jung KH, Lee DG, et al. 20(S)Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin［J］. Oncotarget, 2014, 5(12): 4438-4451. ［16］ Li Q, Li Y, Wang X, et al. Cotreatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release［J］. Mol Carcinog, 2011, 50(10): 760-769. ［17］ Yu Y, Zhang C, Liu L, et al. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas［J］. Exp Ther Med, 2013, 5(3): 761-766. ［18］ Kim SJ, Yuan HD, Chung SH. Ginsenoside Rg1 suppresses hepatic glucose production via AMP-activated protein kinase in HepG2 cells［J］. Biol Pharm Bull, 2010, 33(2): 325-328. ［19］ Yuan HD, Kim do Y, Quan HY, et al. Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3β via AMPactivated protein kinase to inhibit hepatic glucose production in HepG2 cells［J］. Chem Biol Interact, 2012, 195(1): 35-42. ［20］ Wu R, Ru Q, Chen L, et al. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22bearing mice［J］. J Food Sci, 2014, 79(7): H1430-1435.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells [J]. Journal of International Oncology, 2023, 50(4): 241-243.
[6]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke. Diagnostic value of serum TIM-3 in patients with liver cancer [J]. Journal of International Oncology, 2022, 49(9): 537-542.
[7]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng. Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer [J]. Journal of International Oncology, 2022, 49(10): 592-596.
[8]	Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer [J]. Journal of International Oncology, 2022, 49(10): 635-638.
[9]	Du Jiahang, Chen Dong, Chen Yaoting. Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2021, 48(9): 572-.
[10]	Han Baojun. Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance [J]. Journal of International Oncology, 2021, 48(7): 415-419.
[11]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang. Progress of biomarkers in liver cancer [J]. Journal of International Oncology, 2021, 48(4): 241-245.
[12]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing. IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway [J]. Journal of International Oncology, 2021, 48(12): 711-715.
[13]	Liu Junguo, Zhang Jinjuan, Wang Yijun. Clinical application progress of variations in the technique of liver partition from ALPPS [J]. Journal of International Oncology, 2020, 47(8): 492-495.
[14]	Xin Ruiqiang, Song Xiaoping, Zhang Fan, Sun Ying, Wang Tao, Sun Wei. Mechanism of SUMO regulating XBP1 mediated endoplasmic reticulum stress on the progression of liver cancer [J]. Journal of International Oncology, 2020, 47(7): 397-403.
[15]	Zhao Chuanxi, Zhu Tingting, Liu Mingguo, Cao Lili. Advances of Krüppel-like factors in hepatocellular carcinoma [J]. Journal of International Oncology, 2020, 47(2): 119-122.